Literature DB >> 6990965

The treatment of acute lymphoblastic leukaemia.

J V Simone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6990965     DOI： 10.1111/j.1365-2141.1980.tb03804.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia.

Authors:  Kanhatai Chiengthong; Chupong Ittiwut; Sasipa Muensri; Jiratchaya Sophonphan; Darintr Sosothikul; Panya Seksan; Koramit Suppipat; Kanya Suphapeetiporn; Vorasuk Shotelersuk
Journal:  Haematologica       Date:  2015-09-24       Impact factor: 9.941

2.  Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism.

Authors:  Y Kato; T Matsushita; H Uchida; S Egi; T Yokoyama; K Mohri
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia.

Authors:  A D Pearson; A W Craft; E J Eastham; G W Aherne; P Littleton; G L Pearson; A N Campbell
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.

Authors:  F Innocenti; R Danesi; A Di Paolo; B Loru; C Favre; M Nardi; G Bocci; D Nardini; P Macchia; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

5.  6-Mercaptopurine: apparent lack of relation between prescribed dose and biological effect in children with leukaemia.

Authors:  S Herber; L Lennard; J S Lilleyman; J Maddocks
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

Review 6.  Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.

Authors:  Kjeld Schmiegelow; Stine N Nielsen; Thomas L Frandsen; Jacob Nersting
Journal:  J Pediatr Hematol Oncol       Date:  2014-10       Impact factor: 1.289
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.